Scientific article
Open access

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

Published inESMO open, vol. 7, no. 2, 100392
Publication date2022-04
First online date2022-02-16

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

  • Colorectal cancer
  • Neuroendocrine tumours
  • Oesophagus cancer
  • Pancreatic cancer
  • Stomach cancer
  • Gastrointestinal Neoplasms / drug therapy
  • Humans
  • Immunotherapy
  • Medical Oncology
Citation (ISO format)
KOSSLER, Thibaud et al. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective. In: ESMO open, 2022, vol. 7, n° 2, p. 100392. doi: 10.1016/j.esmoop.2022.100392
Main files (1)
Article (Published version)
ISSN of the journal2059-7029

Technical informations

Creation10/13/2022 9:38:45 AM
First validation05/23/2023 2:22:08 PM
Update time05/23/2023 2:22:08 PM
Status update05/23/2023 2:22:08 PM
Last indexation02/01/2024 10:07:55 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack